Recent News

• 03.27.2025 - BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
• 03.17.2025 - Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
• 03.04.2025 - Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
• 02.25.2025 - Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
• 01.29.2025 - Dermata to Present on BioPub on January 31, 2025
• 01.23.2025 - Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Recent Filings

• 03.25.2025 - 8-K Current report
• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.05.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.05.2025 - EFFECT Notice of Effectiveness
• 02.04.2025 - D/A Notice of Exempt Offering of Securities
• 02.03.2025 - CORRESP Correspondence